GENTA INCORPORATED /DE/
8-K, 1999-01-06
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: KEMPER TAX EXEMPT INSURED INCOME TRUST MULTI STATE SER 41, 24F-2NT, 1999-01-06
Next: SCICLONE PHARMACEUTICALS INC, SC 13G, 1999-01-06




                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                       ----------------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported): November 30, 1998

                                   ----------


                               GENTA INCORPORATED
             (Exact name of registrant as specified in its charter)

                         Commission file number 0-19635


                  Delaware                            33-0326866
       (State or other jurisdiction of     (I.R.S. Employer Identification
       incorporation or organization)                  Number)



                 3550 General Atomics Court, San Diego, CA 92121
                    (Address of principal executive offices)
                                   (Zip Code)


                                 (619) 455-2700
               Registrant's telephone number, including area code




<PAGE>



                               GENTA INCORPORATED
                                    FORM 8-K
                                 CURRENT REPORT

                                TABLE OF CONTENTS

Item 5.              Other Events............................................3

Signature....................................................................4

                                      - 2 -


<PAGE>


Item 5.         OTHER EVENTS

         Genta Incorporated (the "Company"), entered into a Settlement Agreement
and Release dated as of November 30, 1998 (the "Settlement  Agreement") with LBC
Capital  Resources,  Inc. ("LBC"),  Paramount Capital,  Inc. ("PCI"),  Paramount
Capital Asset Management,  Inc. ("PCAM"), The Aries Fund, a Cayman Islands trust
("Aries  Trust"),  Aries Domestic Fund, L.P.  ("Aries  Domestic,"  together with
Aries Trust, the "Aries Funds" and, together with Aries Trust, PCI and PCAM, the
"Paramount  Group").  Pursuant to the Settlement  Agreement,  LBC agreed,  inter
alia,  to dismiss with  prejudice a  complaint,  dated April 2, 1998 against the
Company and the  Paramount  Group in the United  States  District  Court for the
Southern District of New York,  captioned LBC Capital  Resources,  Inc. v. Genta
Incorporated,  et al.,  Civil  Action  No. 98 CIV  2491-CSH.  See the  Company's
Quarterly Report on Form 10-Q for the period ended September 30, 1998, under the
caption "Legal Proceedings." Additionally,  pursuant to the Settlement Agreement
and without  admitting any liability,  the Company agreed: to issue to LBC 2,900
shares of Series D  Convertible  Preferred  Stock,  par value  $0.001  per share
("Series D Preferred Stock") of the Company which are presently convertible into
an aggregate of  approximately  307,285 shares of common stock, par value $0.001
per share, (the "Common Stock") of the Company at a conversion price of $0.94375
per  share;  to  issue  to LBC or its  designee  five-year  warrants  (the  "LBC
Warrants")  to acquire  700,000  shares of Common Stock at an exercise  price of
$0.52  per  share;  to make  certain  payments  to LBC  totalling  approximately
$182,000;  and to pay to LBC, upon the exercise of certain  warrants held by the
Aries  Funds,  a  commission  equal  to up to  $150,000  in the  aggregate.  The
respective  conversion and exercise  prices of the Series D Preferred  Stock and
the LBC  Warrants  are  subject to  adjustment  upon the  occurrence  of certain
events.

                                      - 3 -




<PAGE>


                                    SIGNATURE

           Pursuant to the requirements of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: January 6, 1999


                             GENTA INCORPORATED


                             /s/Kenneth G. Kasses
                             ----------------------------------
                             Kenneth G. Kasses, Ph.D.
                             Chairman of the Board of Directors, President,
                             Principal Executive Officer and Principal
                             Financial Officer

                                      - 4 -



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission